secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001193125-23-275300
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix presents updated clinical guidance, NX-2127 Phase 1 details
-----------------------------------------------------------------

- Investor presentation includes updated guidance on clinical programs.
- Additional detail on Phase 1 trial of NX-2127 for B-cell malignancies provided.
- Meetings with analysts and investors begin November 13, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000119312523275300/0001193125-23-275300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000119312523275300/d541490d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-275300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer